Ultragenyx Pharmaceutical News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 21 05:30

Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

BreakingsDec 21 05:30

Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88

Futu NewsDec 21 03:35 · Ratings

Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TipRanksDec 21 02:39 · Ratings

Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70

Futu NewsDec 21 02:31 · Ratings

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88

BenzingaDec 20 21:38 · Ratings

NHS England Rolls Out Evkeeza ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older With Homozygous Familial Hypercholesterolaemia (HoFH)

GlobeNewswireDec 20 16:00

Express News | Ultragenyx Pharmaceutical Inc - Primary Endpoint Is Improvement in Cognition Assessed by Bayley-4

BreakingsDec 20 05:06

Express News | Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating Gtx-102 in Angelman Syndrome

BreakingsDec 20 05:05

Express News | Ultragenyx Submits Biologics License Application to the U.S. FDA for Ux111 Aav Gene Therapy for the Treatment of Sanfilippo Syndrome Type a (Mps Iiia)

BreakingsDec 19 21:00

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswireDec 19 21:00

Express News | Ultragenyx Pharmaceutical Inc : Jefferies Cuts Target Price to $123 From $124

BreakingsDec 17 14:05

Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81

Futu NewsDec 16 19:31 · Ratings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)

TipRanksDec 16 19:30 · Ratings

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)

TipRanksDec 16 14:40 · Ratings

TD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TipRanksDec 11 18:48 · Ratings

Mereo Stock Gains as Jefferies Starts Coverage With Buy Rating

Seeking AlphaDec 7 01:10

Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Business And Shares Still Trailing The Industry

Simply Wall StDec 5 01:57

Ultragenyx to Participate in Investor Conferences in December

GlobeNewswireNov 27 05:30

Ultragenyx Pharmaceutical Analyst Ratings

BenzingaNov 21 22:50 · Ratings